SCHEMBL16478702

SCHEMBL16478702

CN1CCC(C)(O)C1=O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16532437 1.00
SCHEMBL16179443 1.00
SCHEMBL23168692 0.86 GRIN1 (0.40)
SCHEMBL19174271 0.86 GRIN1 (0.40)
SCHEMBL16478701 0.78
SCHEMBL761689 0.75
SCHEMBL23168693 0.75
SCHEMBL16498173 0.75
SCHEMBL22591736 0.74
SCHEMBL8998692 0.73 GRIN1 (0.37)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11912708-B2 Macrocyclic heterocycles and uses thereof KUMQUAT BIOSCIENCES INC. (US) 2024-02-27 US disclosed
US-20230339952-A1 MACROCYCLIC HETEROCYCLES AND USES THEREOF KUMQUAT BIOSCIENCES INC. 2023-10-26 US disclosed
EP-4223752-A1 DEUTERATED HPK1 KINASE INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF Zhuhai Yufan Biotechnologies Co., Ltd (CN) 2023-08-09 EP disclosed
US-20230241050-A1 APPLICATIONS OF HPK1 KINASE INHIBITOR IN PREVENTING AND/OR TREATING ANIMAL PATHOGEN INFECTION Guangzhou Yufan Nantu Biotechnologies Co., Ltd (CN) 2023-08-03 US disclosed
EP-3781563-B1 HPK1 INHIBITORS, PREPARATION METHOD AND APPLICATION THEREOF ZHUHAI YUFAN BIOTECHNOLOGIES CO LTD (CN) 2022-06-29 EP disclosed
WO-2022081912-A2 HETEROCYCLES AND USES THEREOF KUMQUAT BIOSCIENCES INC. (US) 2022-04-21 WO disclosed
WO-2021057872-A1 PROTAC SMALL MOLECULE COMPOUND AND APPLICATION THEREOF 珠海宇繁生物科技有限责任公司 2021-04-01 WO disclosed
EP-3307741-B1 POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARIC M2 RECEPTOR Bayer Pharma AG (DE) 2020-10-28 EP disclosed
WO-2016198342-A1 POSITIVE ALLOSTERIC MODULATORS OF MUSCARINIC M2 RECEPTOR BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2016-12-15 WO disclosed
US-8987268-B2 Pyrrolopyridazine JAK3 inhibitors and their use for the treatment of inflammatory and autoimmune diseases BRISTOL-MYERS SQUIBB COMPANY (US) 2015-03-24 US disclosed
US-20140011800-A1 PYRROLOPYRIDAZINE JAK3 INHIBITORS AND THEIR USE FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES BRISTOL-MYERS SQUIBB COMPANY 2014-01-09 US disclosed